All News

Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis.

Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Phase 3 data presented at ISPAD found that teplizumab-mzwv (Tzield) was better at slowing the progression of type 1 diabetes (T1D) in newly diagnosed children and adolescents.

With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.

Researchers noted that adverse pregnancy outcomes are more of an indicator of pre-pregnancy cardiovascular risk rather than a primary cause of postpartum risk.

No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.

Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer.

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo.

New research found that people who routinely eat high amounts of red meat have a 62% higher risk of developing type 2 diabetes, supporting dietary recommendations to limit red meat consumption.

During a recent Institute for Value-Based Medicine® event, speakers discussed the use of immunotherapy and targeted therapy to treat melanoma and managing the toxicities of these treatments.

Of the 333 patients with psoriatic arthritis (PsA) and 457 patients with axial spondyloarthritis (axSpA), there were 1.09 serious infections per 100 patient-years.

A small portion of these patients with a high inhaled corticosteroid (ICS) dosage will continue use of a second medication to keep their asthma under control, according to study findings.

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP).

The phase 2 KRYSTAL-7 trial evaluated adagrasib plus pembrolizumab in patients with KRAS-mutated non–small cell lung cancer (NSCLC) with high PD-L1 expression. The results demonstrated “encouraging preliminary activity.”

“There are things more important than our discomfort, and there are things that are more important than even our fear—inclusion is more important,” said Erica Marsh, MD, MSCI. “Our care of our patients and loved ones is more important, and our existence tomorrow has to be more important than our fears today.”

The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the relationship between LEP and myelodysplastic syndrome (MDS).

Three US senators asked the Social Security Administration to respond to a report saying it reduced or suspended benefits for those who received COVID-19 relief payments; mifepristone, a drug taken to help manage miscarriages, remains widely unavailable to patients experiencing pregnancy loss; pharmaceutical companies are beginning trials to get weight-loss shots approved for patients with obesity 6 years and older.

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space.

A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo highlighted trends in fertility care amid the turbulent landscape following the Dobbs decision.